Company Overview and News
SAN FRANCISCO (Reuters) - Tariffs are starting to bite big manufacturers and Wall Street could get another bout of caution and uncertainty from major industrial companies when a swath of reports comes in over the next week.
HON GEC GE MTSI DB HON GNE
Tariffs are starting to bite big manufacturers and Wall Street could get another bout of caution and uncertainty from major industrial companies when a swath of reports comes in over the next week.
HON GEC GE MTSI DB HON GNE
Good day, ladies and gentlemen, and welcome to Honeywell's Second Quarter Earnings Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Mark Macaluso, Vice President of Investor Relations.
HON DUAVF AM HON
(Reuters) - U.S. industrial conglomerate Honeywell International Inc (HON.N) said on Friday it had started sourcing some of its components from countries other than China to counter growing costs related to a tariff war between the world’s two largest economies.
Honeywell International Inc. (HON - Free Report) reported better-than-expected results for second-quarter 2018. Earnings & Revenues Adjusted earnings in the reported quarter came in at $2.12 per share, outpacing the Zacks Consensus Estimate of $2.01. The bottom line also improved 18% year over year. This upside primarily stemmed from the company’s stellar operational performance during the quarter.
HON HON 6501 RAVN SSUMF HTHIY SSUMY
When Honeywell International Inc. (NYSE: HON) reported its most recent quarterly results before the markets opened on Friday, it posted $2.12 in earnings per share (EPS) and $10.92 billion in revenue. The consensus estimates had called for $2.01 in EPS and revenue of $10.8 billion. In the same period of last year, Honeywell said it had EPS of $1.80 on $10.08 billion in revenue.
Global diversified technology and manufacturing firm Honeywell International Inc. (HON - Free Report) has a balanced mix of long and short-cycle businesses. With a flexible yet disciplined focus on cost and productivity, HON remains focused on increasing its presence in high-growth regions. However, despite HON's proactive restructuring initiatives, it is yet to witness signs of stabilization in a number of its major end markets.
CFIN HON RF.PRB RF.PRA HON KDP CIWV RF
With all the negative news regarding Papa John’s CEO (PZZA - Free Report) and Pizza Hut’s continuous drag on Yum (YUM - Free Report) , it seems as if Domino’s (DPZ - Free Report) stock has a dominant stance amongst its pizza competitors.
WFC WFCNP HON WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
E*TRADE Financial (ETFC - Free Report) just released its second quarter financial results, posting adjusted earnings of $0.95 per share and revenues of $710 million.
WFC WFCNP HON WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON ETFC WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Discount retailer Five Below (FIVE - Free Report) has been on a staggering uptrend recently, soaring 62.8% so far this year and reaching an all-time high of $108.96 per share on Thursday.
WFC WFCNP HON WFC.WS XKE WFC.PRL WFC.PRJ DLTR WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON WFC.PRN DG WFC.PRY WFC.PRX FIVE WFC.PRW WFC.PRV
Skyworks Solutions (SWKS - Free Report) just released its latest quarterly results, posting earnings of $1.64 per share and revenues of $894.3 million.
WFC WFCNP HON WFC.WS GEC GE WFC.PRL WFC.PRJ WFC.PRT SWKS WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON WFC.PRN GNE WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Microsoft (MSFT - Free Report) just released its Q4 and fiscal 2018 financial results, posting adjusted earnings of $1.13 per share and revenues of $30.09 billion.
WFC WFCNP HON WFC.WS GEC GE WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO HON WFC.PRN GNE MSFT WFC.PRY WFC.PRX WFC.PRW WFC.PRV
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to LSE:HON / HONEYWELL INTERNATIONAL INC on message board site Silicon Investor.